Skip to content
Review Open access

Targeting ferroptosis in ocular diseases: mechanisms, clinical implications, and therapeutic horizons.

Sep 2026 · International Journal of Ophthalmology · Vol 19 9, pp. 1858-1877 · 0 citations
Medicine

Abstract

Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, has been increasingly implicated in selected ocular diseases, although its causal relevance varies across disease entities. The retina and retinal pigment epithelium are biologically susceptible to ferroptosis-related injury because of their high oxygen demand, abundant polyunsaturated lipids, mitochondrial activity, light exposure, and tightly regulated iron handling. This review summarizes core mechanisms of ocular ferroptosis, including iron uptake and export, glutathione-glutathione peroxidase 4 (GPX4)-dependent antioxidant defense, lipid peroxidation, mitochondrial dysfunction, neuroinflammation, and blood-retina barrier disruption. We discuss evidence from major degenerative, vascular, ischemic, hereditary, infectious, and immune-mediated retinal diseases, with particular attention to glaucoma, age-related macular degeneration, diabetic retinopathy, ocular toxoplasmosis, uveitis, retinal vasculitis, and inflammatory chorioretinopathy. We also evaluate ferroptosis-targeted therapeutic strategies, proposed operational criteria for defining ferroptosis in retinal disease, and candidate structural, functional, biochemical, and imaging endpoints for future translational studies. Current evidence supports ferroptosis as a context-dependent contributor to retinal injury rather than a uniform pathogenic mechanism. Future studies should integrate cell-type-resolved biomarkers, lipidomic and imaging readouts, functional rescue experiments, and clinically meaningful visual outcomes to clarify when ferroptosis modulation may support vision preservation.

Read PDF

Similar papers

Review Open access Sep 2026

Ferroptosis in retinal neurodegeneration: mechanistic vulnerability, therapeutic targeting, and translational barriers

Current evidence supporting ferroptosis-related vulnerability in retinal neurodegenerative diseases is synthesized and emerging enabling strategies are evaluated, including nanocarrier-based delivery, long-acting gene modulation, and biomarker frameworks integrating ocular fluids, imaging, multi-omics, and artificial i...

Guang-Guang Wu, Su-Yu Wang, Zi-Yi Chen et al. · 0 citations
Review Open access Sep 2026

Ferroptosis in neonatal and paediatric disease: From molecular mechanism to therapeutic target.

A prioritized translational framework that focuses on juvenile animal models, age-stratified pharmacokinetics, and patient-derived organoids is proposed to provide guidance for translating clinical practice to this vulnerable population of children.

Cheng-Xiang Zhang, L.-E. Ding, Dan-Chun Wang et al. · 0 citations
Review Aug 2026

Ferroptosis in Intestinal Diseases: Molecular Mechanisms, Therapeutic Potential, and Future Perspectives.

This review systematically integrates the latest insights into the molecular mechanisms regulating ferroptosis, the pathophysiology of various intestinal diseases, and translational therapeutic strategies to provide a comprehensive roadmap for leveraging ferroptosis to manage intestinal diseases.

Liyan Deng, Kangdi Liu, Jia-Li Peng et al. · 0 citations
Review Open access Sep 2026

Ferroptosis in autoimmune uveitis: potential links to blood–retinal barrier dysfunction and retinal inflammation

This Mini Review examines ferroptosis as a potential contributor to BRB dysfunction and retinal inflammation and separates direct AU/EAU findings from extrapolated evidence and highlights priorities for preclinical validation.

Jun Wang, He-Ping Li, Hao-Han Xiong et al. · 0 citations
Review Aug 2026

Ferroptosis and Alzheimer's disease: Neuroimmune crosstalk and pharmacological opportunities.

Although available evidence supports an association between ferroptosis-related processes and AD pathobiology, no single marker is sufficient to establish ferroptosis in human AD tissue, which restricts the diagnostic and therapeutic interpretation of ferroptosis in AD.

Yelizaveta A. Marakhovskaya, A. Churov, Mikhail Arbatsky et al. · 0 citations
Review Open access Aug 2026

Ferroptosis in skeletal muscle: from molecular mechanisms to therapeutic interventions

This review systematically delineates the core molecular machinery of ferroptosis, including the system Xc−-glutathione-GPX4 axis, dysregulated iron metabolism, and lipid peroxidation, together with key regulatory networks involving p53, Nrf2, and AMPK.

K. Ren, Yijia An, Kaili Zhou et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.